Particle.news

Download on the App Store

Liraglutide Pilot Study Halves Chronic Migraine Days, Paves Way for Randomized Trials

Lowering cerebrospinal fluid pressure produced significant migraine relief without affecting weight in the initial trial.

Image
Image
Image

Overview

  • An Italian open-label study of 31 obese adults saw average monthly migraine days drop from about 20 to 11 over 12 weeks of daily liraglutide injections.
  • Participants’ body weight remained stable, indicating that headache reductions were not tied to weight loss.
  • Around 40% of subjects experienced mild gastrointestinal side effects such as nausea and constipation, but none discontinued treatment.
  • Investigators attribute the migraine relief to reductions in cerebrospinal fluid pressure rather than metabolic changes.
  • Researchers plan a larger randomized, double-blind trial to measure intracranial pressure directly and test other GLP-1 receptor agonists.